Cost-effectiveness analysis of vaccination against human papilloma virus (HPV) types 6, 11, 16 and 18 in Spain;Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España

Vacunas

Volumn 9, Issue 1, 2008, Pages 3-11

  Largeron, N ^a   Remy V ^a   Oyee, J ^b   San Martin M ^c   Cortes J ^d   Olmos, L ^e  

^a SANOFI PASTEUR   (France)

^b MAPI VALUES   (United States)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^d Ginecología Oncológica   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cervical cancer screening; Cost effectiveness; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER SCREENING; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; PRECANCER; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; SPAIN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION;

EID: 45249096506     PISSN: 15769887     EISSN: 15788857     Source Type: Journal    
DOI: 10.1016/S1576-9887(08)71915-0     Document Type: Article

References (39)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence world wide. 2004. IARC Cancer Base No. 5, version 2.0. Lyon: IARCPress; 2002.
2. Marzo-Castellejo M, Cierco Peguero P, Del Cura González I. Prevención del cáncer de cérvix. Aten Primaria. 2005;36:328-33.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
4. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-5.
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157-64.
6. Cerdá Mota T, Salas Trejo D. Detección precoz del cáncer. Situación del cáncer en España. Ministerio de Sanidad y Consumo [Consultado Oct 2007]. Disponible en: http://www. webpacientes.org/docs/cancer-msc.pdf
7. Bray F, Loos AH, McCarron P, et al. Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of Screening. Cancer Epidemiol Biomarkers Prev. 2005;14:677-86.
8. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against Human Papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
9. The FUTURE II Study Group. Quadrivalent vaccine against Human Papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
10. Ministerio de Sanidad y Consumo. El Consejo Interterritorial aprueba la inclusión de la vacuna del virus del papiloma humano en el calendario vacunal del SNS por unanimidad. Notas de Prensa. 10 de octubre de 2007. Disponible en: http://www.msc.es/gabinetePrensa/notaPrensa/desarrolloNotaPrensa. jsp?id=992
11. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-71.
12. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-9.
13. Bergeron C, Largeron N, Mcallister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent Human Papillomavirus vaccine in France. Int J Technol Ass Health Care. [En prensa].
14. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530-6.
15. Herruzo R, Carmona M, Rodriguez-Escudero F, et al. Cáncer invasivo de cervix en España (1995). Encuesta de la Sociedad Española de Ginecología y Obstetricia. Prog Obstet Ginecol. 2005;48:247-57.
16. Suris JC, Dexeus S. Survival in Cervical cancer. Eur J Gynaecol Oncol. 1998;19:11-3.
17. Siebert U, Sroczynski G, Hillemanns P. The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Pub Health. 2006;16:185-92.
18. Cosson M. Hystérectomies pour pathologies bénignes. Paris: Masson; 1997.
19. Castellsague X, Cohet C, Puig Tintoré LM, et al. Burden of genital warts in Spain. EUROGIN. October 4-6 2007, Monte Carlo, Monaco.
20. Puig-Tintoré LM, Castellsague X, Torne A, et al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study, a population-based survey in Spain. J Low Genit Tract Dis. 2008;12:82-9.
21. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess. 2004;8:iii1-78.
22. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-9.
23. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;91:626-31.
24. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280-93.
25. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-9.
26. Villa LL, Costa RL, Pefta C, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-66.
27. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2006;96:143-150.
28. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing Human Papillomavirus Vaccination Strategies. Emerg Infec Dis. 2007;13:28-41.
29. Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762-75.
30. Mata M, Antoñanzas F, Tafalla M, Sanz P. El coste de la diabetes tipo 2 en España. El estudio CODE-2. Gac Sanit. 2002;16:511-20.
31. Castellsague X, Rémy V, Puig-Tintoré LM, et al. Cervical Cancer Screening And Management Costs In Spain. 33rd European Congress of Cytology, 14-17 October 2007, Madrid, Spain.
32. Rash RM, Tome A, Castro M, Cararach M, Ferrer E, De Sanjose S. Evaluating the costs of follow-up and treatment of women with abnormal cervical cytology in Spain. Health Technology Assessment International. June 17-20 2007, Barcelona, Spain.
33. De Sanjose S, Ferrer E, Ferko N, Gauthier A, Seradilla C, Bosch F. Adaptation of a health economic model of the natural history of HPV infection and cervical cancer for Spain. 23rd International Papillomavirus conference & clinical workshop (IPV); Prague, Czech Republic, 2006.
34. Lenne X, Diez Domingo J, Gil A, Ridao A, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain. Results from a dynamic model. Vaccine. 2006;24:6980-9.
35. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference. Mexico City, Mexico, 2004.
36. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of human papillomavirus 16/18 vaccine. J Nat Can Inst. 2004;96:604-15.
37. Vicente Ortún. 30.000 Euros Por AVAC. Economía y Salud. 2004;17. Disponble en: www.econ.upf.es/~ortun/publications/30000.pdf
38. Crott R. Economic analysis of HPV-vaccines: Not so simple? Vaccine. 2007;25:7717.
39. Villa L. Quadrivalent Human Papillomavirus (HPV) type 6/11/16/18 L1 virus-like particle vaccine: first analysis of cross-protection against cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. EUROGIN. October 4-6 2007, Monte Carlo, Monaco.